| __timestamp | BioCryst Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 5758000 |
| Thursday, January 1, 2015 | 1896000 | 8423000 |
| Friday, January 1, 2016 | 2699000 | 11986000 |
| Sunday, January 1, 2017 | 1702000 | 15215000 |
| Monday, January 1, 2018 | 471000 | 15356000 |
| Tuesday, January 1, 2019 | 4101000 | 16660000 |
| Wednesday, January 1, 2020 | 1676000 | 52459000 |
| Friday, January 1, 2021 | 7264000 | 75061000 |
| Saturday, January 1, 2022 | 6594000 | 87221000 |
| Sunday, January 1, 2023 | 4661000 | 83779000 |
Unlocking the unknown
In the dynamic world of biopharmaceuticals, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Supernus Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Supernus Pharmaceuticals consistently outpaced BioCryst in cost of revenue, peaking in 2022 with a staggering 87 million USD, a 51% increase from 2019. In contrast, BioCryst's cost of revenue saw a more modest rise, reaching its zenith in 2021 at 7.3 million USD, a significant leap from its 2014 figure of just 122,000 USD. This disparity highlights Supernus's aggressive growth strategy, while BioCryst's more conservative approach reflects its focus on niche markets. As the biopharma landscape evolves, these trends offer valuable insights into each company's operational priorities and market positioning.
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
Who Generates Higher Gross Profit? Supernus Pharmaceuticals, Inc. or BioCryst Pharmaceuticals, Inc.